Upfront intensive chemo-immunotherapy with autograft in 199 adult mantle cell lymphoma patients: prolonged survival and cure potentiality at long term: Bone Marrow Transplantation

S. Cortelazzo; M. Mian; A. Evangelista; L. Devizzi; P. Corradini; M. Magni; M. Ladetto; S. Ferrero; A. Rossi; A.M. Barbui; C. Patti; A. Costa; U. Vitolo; A. Chiappella; F. Benedetti; A.J.M. Ferreri; P. Nicoli; L. Rigacci; C. Castellino; A.M. Gianni; A. Rambaldi; C. Tarella

doi:10.1038/s41409-021-01391-x

Upfront intensive chemo-immunotherapy with autograft in 199 adult mantle cell lymphoma patients: prolonged survival and cure potentiality at long term: Bone Marrow Transplantation

S. Cortelazzo, M. Mian, A. Evangelista, L. Devizzi, P. Corradini, M. Magni, M. Ladetto, S. Ferrero, A. Rossi, A.M. Barbui, C. Patti, A. Costa, U. Vitolo, A. Chiappella, F. Benedetti, A.J.M. Ferreri, P. Nicoli, L. Rigacci, C. Castellino, A.M. GianniA. Rambaldi, C. Tarella

Research output: Contribution to journal › Article › peer-review

Original language	English
Pages (from-to)	2606-2609
Number of pages	4
Journal	Bone Marrow Transplant.
Volume	56
Issue number	10
DOIs	https://doi.org/10.1038/s41409-021-01391-x
Publication status	Published - 2021

Keywords

antineoplastic agent
adult
autograft
autotransplantation
human
immunotherapy
mantle cell lymphoma
multimodality cancer therapy
Adult
Antineoplastic Combined Chemotherapy Protocols
Autografts
Combined Modality Therapy
Humans
Immunotherapy
Lymphoma, Mantle-Cell
Transplantation, Autologous

Access to Document

10.1038/s41409-021-01391-x

https://www.scopus.com/inward/record.uri?eid=2-s2.0-85109958348&doi=10.1038%2fs41409-021-01391-x&partnerID=40&md5=ca38fe7575b231bedd65bb1a7f8b7a1b

Cite this

Cortelazzo, S., Mian, M., Evangelista, A., Devizzi, L., Corradini, P., Magni, M., Ladetto, M., Ferrero, S., Rossi, A., Barbui, A. M., Patti, C., Costa, A., Vitolo, U., Chiappella, A., Benedetti, F., Ferreri, A. J. M., Nicoli, P., Rigacci, L., Castellino, C., ... Tarella, C. (2021). Upfront intensive chemo-immunotherapy with autograft in 199 adult mantle cell lymphoma patients: prolonged survival and cure potentiality at long term: Bone Marrow Transplantation. Bone Marrow Transplant., 56(10), 2606-2609. https://doi.org/10.1038/s41409-021-01391-x

Cortelazzo, S, Mian, M, Evangelista, A , Devizzi, L , Corradini, P , Magni, M, Ladetto, M, Ferrero, S, Rossi, A, Barbui, AM, Patti, C, Costa, A, Vitolo, U, Chiappella, A , Benedetti, F , Ferreri, AJM, Nicoli, P, Rigacci, L, Castellino, C, Gianni, AM, Rambaldi, A & Tarella, C 2021, 'Upfront intensive chemo-immunotherapy with autograft in 199 adult mantle cell lymphoma patients: prolonged survival and cure potentiality at long term: Bone Marrow Transplantation', Bone Marrow Transplant., vol. 56, no. 10, pp. 2606-2609. https://doi.org/10.1038/s41409-021-01391-x

@article{fccb0d18123d4e6386ba5d5ad8a21646,

title = "Upfront intensive chemo-immunotherapy with autograft in 199 adult mantle cell lymphoma patients: prolonged survival and cure potentiality at long term: Bone Marrow Transplantation",

keywords = "antineoplastic agent, adult, autograft, autotransplantation, human, immunotherapy, mantle cell lymphoma, multimodality cancer therapy, Adult, Antineoplastic Combined Chemotherapy Protocols, Autografts, Combined Modality Therapy, Humans, Immunotherapy, Lymphoma, Mantle-Cell, Transplantation, Autologous",

author = "S. Cortelazzo and M. Mian and A. Evangelista and L. Devizzi and P. Corradini and M. Magni and M. Ladetto and S. Ferrero and A. Rossi and A.M. Barbui and C. Patti and A. Costa and U. Vitolo and A. Chiappella and F. Benedetti and A.J.M. Ferreri and P. Nicoli and L. Rigacci and C. Castellino and A.M. Gianni and A. Rambaldi and C. Tarella",

note = "Cited By :1 Export Date: 17 February 2022 CODEN: BMTRE Correspondence Address: Tarella, C.; Onco-Hematology Unit, Italy; email: corrado.tarella@unimi.it References: Herrmann, A., Hoster, E., Zwingers, T., Brittinger, G., Engelhard, M., Meusers, P., Improvement of overall survival in advanced stage mantle cell lymphoma (2009) J Clin Oncol., 27, pp. 511-518; Hoster, E., Dreyling, M., Klapper, W., Gisselbrecht, C., van Hoof, A., Kluin-Nelemans, H.C., A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma (2008) Blood., 111, pp. 558-565. , COI: 1:CAS:528:DC%2BD1cXns1Cgtw%3D%3D; Geisler, C.H., Kolstad, A., Laurell, A., Andersen, N.S., Pedersen, L.B., Jerkeman, M., Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma (2008) Blood., 112, pp. 2687-2693. , COI: 1:CAS:528:DC%2BD1cXht1SrtLfE; Magni, M., Di Nicola, M., Carlo-Stella, C., Matteucci, P., Devizzi, L., Tarella, C., High-dose sequential chemotherapy and in vivo rituximab-purged stem cell autografting in mantle cell lymphoma: a 10-year update of the R-HDS regimen (2009) Bone Marrow Transpl, 43, pp. 509-511. , COI: 1:CAS:528:DC%2BD1MXjs1KgsL0%3D; Romaguera, J.E., Fayad, L.E., Feng, L., Hartig, K., Weaver, P., Rodriguez, M.A., Ten-year follow-up after intense chemoimmunotherapy with Rituximab-HyperCVAD alternating with Rituximab-high dose methotrexate/cytarabine (R-MA) and without stem cell transplantation in patients with untreated aggressive mantle cell lymphoma (2010) Br J Haematol., 150, pp. 200-208. , COI: 1:CAS:528:DC%2BC3cXhtVegsLzF, PID: 20528872; Gianni, A.M., Magni, M., Martelli, M., Di Nicola, M., Carlo-Stella, C., Pilotti, S., Long-term remission in mantle cell lymphoma following high-dose sequential chemotherapy and in vivo rituximab-purged stem cell autografting (R-HDS regimen) (2003) Blood., 102, pp. 749-755. , COI: 1:CAS:528:DC%2BD3sXlslGiurs%3D; Swerdlow, S.H., Campo, E., Pileri, S.A., Harris, N.L., Stein, H., Siebert, R., The 2016 revision of the World Health Organization classification of lymphoid neoplasms (2016) Blood., 127, pp. 2375-2390. , COI: 1:CAS:528:DC%2BC2sXjs1ans74%3D; Hermine, O., Hoster, E., Walewski, J., Bosly, A., Stilgenbauer, S., Thieblemont, C., Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL Younger): a randomised, open-label, phase 3 trial of the European Mantle Cell Lymphoma (2016) Lancet., 388, pp. 565-575. , COI: 1:CAS:528:DC%2BC28XpvV2ru7o%3D; Le Gouill, S., Thieblemont, C., Oberic, L., Moreau, A., Bouabdallah, K., Dartigeas, C., Rituximab after Autologous Stem-Cell Transplantation in Mantle-Cell Lymphoma (2017) N Engl J Med, 377, pp. 1250-1260; Gerson, J.N., Handorf, E., Villa, D., Gerrie, A.S., Chapani, P., Li, S., Survival Outcomes of Younger Patients With Mantle Cell Lymphoma Treated in the Rituximab Era (2019) J Clin Oncol, 37, pp. 471-480. , COI: 1:CAS:528:DC%2BC1MXht1CisbvP; Romaguera, J.E., Fayad, L., Rodriguez, M.A., Broglio, K.R., Hagemeister, F.B., Pro, B., High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine (2005) J Clin Oncol, 23, pp. 7013-7023. , COI: 1:CAS:528:DC%2BD2MXhtFCrsbnO; Ladetto, M., Cortelazzo, S., Ferrero, S., Evangelista, A., Mian, M., Tavarozzi, R., Lenalidomide maintenance after Autologous Stem-Cell Transplantation in Mantle-Cell Lymphoma (MCL): results of a “Fondazione Italiana Linfomi” (FIL) multicenter randomised phase III trial. Lancet (2021) Hematology, 8, pp. e34-e44. , January",

year = "2021",

doi = "10.1038/s41409-021-01391-x",

language = "English",

volume = "56",

pages = "2606--2609",

journal = "Bone Marrow Transplant.",

issn = "0268-3369",

publisher = "Springer Nature",

number = "10",

}

TY - JOUR

T1 - Upfront intensive chemo-immunotherapy with autograft in 199 adult mantle cell lymphoma patients: prolonged survival and cure potentiality at long term

T2 - Bone Marrow Transplantation

AU - Cortelazzo, S.

AU - Mian, M.

AU - Evangelista, A.

AU - Devizzi, L.

AU - Corradini, P.

AU - Magni, M.

AU - Ladetto, M.

AU - Ferrero, S.

AU - Rossi, A.

AU - Barbui, A.M.

AU - Patti, C.

AU - Costa, A.

AU - Vitolo, U.

AU - Chiappella, A.

AU - Benedetti, F.

AU - Ferreri, A.J.M.

AU - Nicoli, P.

AU - Rigacci, L.

AU - Castellino, C.

AU - Gianni, A.M.

AU - Rambaldi, A.

AU - Tarella, C.

N1 - Cited By :1 Export Date: 17 February 2022 CODEN: BMTRE Correspondence Address: Tarella, C.; Onco-Hematology Unit, Italy; email: corrado.tarella@unimi.it References: Herrmann, A., Hoster, E., Zwingers, T., Brittinger, G., Engelhard, M., Meusers, P., Improvement of overall survival in advanced stage mantle cell lymphoma (2009) J Clin Oncol., 27, pp. 511-518; Hoster, E., Dreyling, M., Klapper, W., Gisselbrecht, C., van Hoof, A., Kluin-Nelemans, H.C., A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma (2008) Blood., 111, pp. 558-565. , COI: 1:CAS:528:DC%2BD1cXns1Cgtw%3D%3D; Geisler, C.H., Kolstad, A., Laurell, A., Andersen, N.S., Pedersen, L.B., Jerkeman, M., Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma (2008) Blood., 112, pp. 2687-2693. , COI: 1:CAS:528:DC%2BD1cXht1SrtLfE; Magni, M., Di Nicola, M., Carlo-Stella, C., Matteucci, P., Devizzi, L., Tarella, C., High-dose sequential chemotherapy and in vivo rituximab-purged stem cell autografting in mantle cell lymphoma: a 10-year update of the R-HDS regimen (2009) Bone Marrow Transpl, 43, pp. 509-511. , COI: 1:CAS:528:DC%2BD1MXjs1KgsL0%3D; Romaguera, J.E., Fayad, L.E., Feng, L., Hartig, K., Weaver, P., Rodriguez, M.A., Ten-year follow-up after intense chemoimmunotherapy with Rituximab-HyperCVAD alternating with Rituximab-high dose methotrexate/cytarabine (R-MA) and without stem cell transplantation in patients with untreated aggressive mantle cell lymphoma (2010) Br J Haematol., 150, pp. 200-208. , COI: 1:CAS:528:DC%2BC3cXhtVegsLzF, PID: 20528872; Gianni, A.M., Magni, M., Martelli, M., Di Nicola, M., Carlo-Stella, C., Pilotti, S., Long-term remission in mantle cell lymphoma following high-dose sequential chemotherapy and in vivo rituximab-purged stem cell autografting (R-HDS regimen) (2003) Blood., 102, pp. 749-755. , COI: 1:CAS:528:DC%2BD3sXlslGiurs%3D; Swerdlow, S.H., Campo, E., Pileri, S.A., Harris, N.L., Stein, H., Siebert, R., The 2016 revision of the World Health Organization classification of lymphoid neoplasms (2016) Blood., 127, pp. 2375-2390. , COI: 1:CAS:528:DC%2BC2sXjs1ans74%3D; Hermine, O., Hoster, E., Walewski, J., Bosly, A., Stilgenbauer, S., Thieblemont, C., Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL Younger): a randomised, open-label, phase 3 trial of the European Mantle Cell Lymphoma (2016) Lancet., 388, pp. 565-575. , COI: 1:CAS:528:DC%2BC28XpvV2ru7o%3D; Le Gouill, S., Thieblemont, C., Oberic, L., Moreau, A., Bouabdallah, K., Dartigeas, C., Rituximab after Autologous Stem-Cell Transplantation in Mantle-Cell Lymphoma (2017) N Engl J Med, 377, pp. 1250-1260; Gerson, J.N., Handorf, E., Villa, D., Gerrie, A.S., Chapani, P., Li, S., Survival Outcomes of Younger Patients With Mantle Cell Lymphoma Treated in the Rituximab Era (2019) J Clin Oncol, 37, pp. 471-480. , COI: 1:CAS:528:DC%2BC1MXht1CisbvP; Romaguera, J.E., Fayad, L., Rodriguez, M.A., Broglio, K.R., Hagemeister, F.B., Pro, B., High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine (2005) J Clin Oncol, 23, pp. 7013-7023. , COI: 1:CAS:528:DC%2BD2MXhtFCrsbnO; Ladetto, M., Cortelazzo, S., Ferrero, S., Evangelista, A., Mian, M., Tavarozzi, R., Lenalidomide maintenance after Autologous Stem-Cell Transplantation in Mantle-Cell Lymphoma (MCL): results of a “Fondazione Italiana Linfomi” (FIL) multicenter randomised phase III trial. Lancet (2021) Hematology, 8, pp. e34-e44. , January

PY - 2021

Y1 - 2021

KW - antineoplastic agent

KW - adult

KW - autograft

KW - autotransplantation

KW - human

KW - immunotherapy

KW - mantle cell lymphoma

KW - multimodality cancer therapy

KW - Adult

KW - Antineoplastic Combined Chemotherapy Protocols

KW - Autografts

KW - Combined Modality Therapy

KW - Humans

KW - Immunotherapy

KW - Lymphoma, Mantle-Cell

KW - Transplantation, Autologous

U2 - 10.1038/s41409-021-01391-x

DO - 10.1038/s41409-021-01391-x

M3 - Article

SN - 0268-3369

VL - 56

SP - 2606

EP - 2609

JO - Bone Marrow Transplant.

JF - Bone Marrow Transplant.

IS - 10

ER -